Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.
Drug: Momelotinib
Momelitinib available as tablets.
Other Name: GSK3070785
Inclusion Criteria: - Written informed consent can be obtained from the patient or legally authorised representative as per local regulations - Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia - 18 years or older (at the time consent is obtained) - The patient is willing to abide by the contraception requirements. - No known hypersensitivity to momelotinib, its metabolites, or any of the formulation excipients
Exclusion Criteria: - Pregnant or breastfeeding female
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
GSK Clinical Trials
Study Director
GlaxoSmithKline